GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » ROA %

Cyfuse Biomedical KK (TSE:4892) ROA % : -5.21% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cyfuse Biomedical KK's annualized Net Income for the quarter that ended in Dec. 2023 was 円-218.52 Mil. Cyfuse Biomedical KK's average Total Assets over the quarter that ended in Dec. 2023 was 円4,193.47 Mil. Therefore, Cyfuse Biomedical KK's annualized ROA % for the quarter that ended in Dec. 2023 was -5.21%.

The historical rank and industry rank for Cyfuse Biomedical KK's ROA % or its related term are showing as below:

TSE:4892' s ROA % Range Over the Past 10 Years
Min: -15   Med: -12.88   Max: 5.9
Current: -13.28

During the past 4 years, Cyfuse Biomedical KK's highest ROA % was 5.90%. The lowest was -15.00%. And the median was -12.88%.

TSE:4892's ROA % is ranked worse than
73.96% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.72 vs TSE:4892: -13.28

Cyfuse Biomedical KK ROA % Historical Data

The historical data trend for Cyfuse Biomedical KK's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK ROA % Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-15.00 5.90 -12.70 -13.05

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only -16.74 -14.29 -17.51 -15.89 -5.21

Competitive Comparison of Cyfuse Biomedical KK's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's ROA % distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's ROA % falls into.



Cyfuse Biomedical KK ROA % Calculation

Cyfuse Biomedical KK's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-589.211/( (4815.337+4214.809)/ 2 )
=-589.211/4515.073
=-13.05 %

Cyfuse Biomedical KK's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-218.516/( (4172.122+4214.809)/ 2 )
=-218.516/4193.4655
=-5.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Cyfuse Biomedical KK  (TSE:4892) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-218.516/4193.4655
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-218.516 / 125.532)*(125.532 / 4193.4655)
=Net Margin %*Asset Turnover
=-174.07 %*0.0299
=-5.21 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Cyfuse Biomedical KK ROA % Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK (TSE:4892) Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK (TSE:4892) Headlines

No Headlines